Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Arthritis & rheumatology Année : 2018

Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study.

K Jaeger Veronika
  • Fonction : Auteur
Gabriele Valentini
  • Fonction : Auteur
Franco Cozzi
  • Fonction : Auteur
Oliver Distler
  • Fonction : Auteur
Paolo Airo
  • Fonction : Auteur
Laszlo Czirjak
  • Fonction : Auteur
Elise Siegert
  • Fonction : Auteur
Edoardo Rosato
  • Fonction : Auteur
Marco Matucci-Cerinic
  • Fonction : Auteur
Cristian Caimmi
  • Fonction : Auteur
Jorg Henes
  • Fonction : Auteur
E Carreira Patricia
  • Fonction : Auteur
Vanessa Smith
  • Fonction : Auteur
Francesco del Galdo
  • Fonction : Auteur
P Denton Christopher
  • Fonction : Auteur
Susanne Ullman
  • Fonction : Auteur
Ellen de Langhe
  • Fonction : Auteur
Valeria Riccieri
  • Fonction : Auteur
Jose Alegre-Sancho Juan
  • Fonction : Auteur
Simona Rednic
  • Fonction : Auteur
Ulf Muller-Ladner
  • Fonction : Auteur
A Walker Ulrich
  • Fonction : Auteur

Résumé

OBJECTIVE: Data on the role of tobacco exposure in systemic sclerosis (SSc; scleroderma) severity and progression are scarce. We aimed to assess the effects of smoking on the evolution of pulmonary and skin manifestations, based on the European Scleroderma Trials and Research group database. METHODS: Adult SSc patients with data on smoking history and a 12-24-month follow-up visit were included. Associations of severity and progression of organ involvement with smoking history and the Comprehensive Smoking Index were assessed using multivariable regression analyses. RESULTS: A total of 3,319 patients were included (mean age 57 years, 85% female); 66% were never smokers, 23% were ex-smokers, and 11% were current smokers. Current smokers had a lower percentage of antitopoisomerase autoantibodies than previous or never smokers (31% versus 40% and 45%, respectively). Never smokers had a higher baseline forced expiratory volume in 1 second/forced vital capacity (FEV1 /FVC) ratio than previous and current smokers (P < 0.001). The FEV1 /FVC ratio declined faster in current smokers than in never smokers (P = 0.05) or ex-smokers (P = 0.01). The baseline modified Rodnan skin thickness score (MRSS) and the MRSS decline were comparable across smoking groups. Although heavy smoking (>25 pack-years) increased the odds of digital ulcers by almost 50%, there was no robust adverse association of smoking with digital ulcer development. CONCLUSION: The known adverse effect of smoking on bronchial airways and alveoli is also observed in SSc patients; however, robust adverse effects of smoking on the progression of SSc-specific pulmonary or cutaneous manifestations were not observed.

Dates et versions

hal-04313464 , version 1 (29-11-2023)

Identifiants

Citer

K Jaeger Veronika, Gabriele Valentini, Eric Hachulla, Franco Cozzi, Oliver Distler, et al.. Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study.. Arthritis & rheumatology, 2018, Arthritis & rheumatology, 70, pp.1829-1834. ⟨10.1002/art.40557⟩. ⟨hal-04313464⟩

Collections

USPC UNIV-LILLE
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More